Dr. Schlumbrecht on the Role of Surgical Resection in Uterine Leiomyosarcoma

Video

In Partnership With:

Matthew P. Schlumbrecht, MD, discusses the role of surgical resection in uterine leiomyosarcoma.

Matthew P. Schlumbrecht, MD, associate professor and co-director of Cancer Prevention and Control, Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the role of surgical resection in uterine leiomyosarcoma.

A prospective clinical trial comparing surgical resection with chemotherapy in uterine leiomyosarcoma would be unlikely to complete full accrual given the rarity of the disease, says Schlumbrecht.

However, retrospective data have demonstrated a potential survival advantage for patients who underwent a complete resection, particularly in those who had negative margins following surgery, says Schlumbrecht.

As such, surgical resection is advisable in eligible patients, after which chemotherapy can be considered.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine